Thrombotic microangiopathy is one of the complications of bone marrow transplantation and is related to other complications such as graft-versus-host disease, veno-occlusive disease, diffuse alveolar hemorrhage, and cytomegalovirus infection. Thrombotic microangiopathy occurred in three out of 12 patients who underwent allogeneic bone marrow transplantation over the past 1 year at our department. We compared the changes in cytokines and other molecules between patients with and without microangiopathy from before conditioning to the early post-transplantation period. All three patients with microangiopathy showed a significant increase of interleukin-12 at the time of leukocyte recovery after transplantation (two-way layout analysis of variance; P Ͻ 0.05), while none of the patients without microangiopathy showed an increase of interleukin-12. No significant differences were found between the two groups with respect to the other cytokines and molecules that were tested. These findings suggested that thrombotic microangiopathy might be predicted at an early stage after bone marrow transplantation by detecting an increase of interleukin-12 at the time of leukocyte recovery. The possibility that thrombotic microangiopathy is related to inflammation or autoimmunity was also suggested.
Thrombotic microangiopathy (TM) is a complication that occurs following either allogeneic or autologous bone marrow transplantation (BMT), [1] [2] [3] [4] [5] [6] affecting up to 6% of patients. 5 The mortality rate from TM ranges from 0 to 100% in various reports. 3, 4 A diagnosis of TM is dependent on finding evidence of microangiopathic hemolytic anemia, eg an increase in fragmented cells, elevation of lactate dehydrogenase (LDH), an increased reticulocyte count, a decreased platelet count, and clinical syndromes.
2 TM following BMT appears to be caused by generalized endoCorrespondence: Dr H Takatsuka, Second Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan Received 6 October 1998; accepted 21 February 1999 thelial cell damage, as documented by the increase in von Willebrand factor in these patients. 7 It has been suggested that the TM is related to endothelial cell damage secondary to irradiation and/or cyclosporin A (CsA) therapy. 5, [7] [8] [9] [10] Many patients who develop TM also have other complications, such as graft-versus-host disease (GVHD), venoocclusive disease (VOD), diffuse alveolar hemorrhage (DAH), or cytomegalovirus (CMV) infection. It has also been proposed that the triggering of a cytokine cascade by endothelial damage may be partly responsible for these various conditions, 3, 5, 8, 11 which may represent different reactions to a common endothelial insult. 11 In the present study, we evaluated the relationship between TM and cytokine levels in BMT patients from before pre-conditioning to after engraftment.
Materials and methods
The subjects were 12 consecutive patients who underwent allogeneic BMT at our department between May 1997 and May 1998. Table 1 shows the age, sex, underlying disease, disease stage, donor type, conditioning regimen, GVHD prophylaxis, and febrile period of the subjects. The following conditioning regimens were used: BU ϩ CY ϩ TBI comprised BU at a dose of 4 mg/kg/day ϫ 2 days, CY at 30 mg/kg/day ϫ 2 days, and TBI at 3 Gy ϫ 4, BU ϩ CY was BU at a dose of 4 mg/kg/day ϫ 4 days and CY at 60 mg/kg/day ϫ 2 days, and CY ϩ TLI was CY at a dose of 50 mg/kg/day ϫ 4 days and TLI at 0.375 Gy ϫ 2 days. For GVHD prophylaxis, the basic treatment was cyclosporin A plus methotrexate plus methyl prednisolone (Chao et al's method 12 ). We made a diagnosis of TM when the reticulocyte count increased and the platelet count decreased in addition to criteria corresponding to grade 2 or higher of the classification system of Zeigler et al 2, 13 (fragmented erythrocytes accounting for at least 1.3% of 2000 counted peripheral blood cells and elevation of LDH). The grading of GVHD was based on the Seattle diagnostic criteria, and the highest grade up to 100 days after transplantation was determined. CsA was infused from day Ϫ1 for 24 h, and kept at a target blood level of 400-600 ng/ml until marrow engraftment, and then the dosage was varied depending on GVHD symptoms after engraftment. If GVHD became worse, CsA dose was increased, dose of methyl prednisolone was increased, or CsA was changed to FK506. Both the bronchoalveolar lavage fluid and per- ALL = acute lymphoblastic leukemia; CR1/2 = 1st/2nd complete remission; SAA = severe aplastic anemia; NR = no remission; CML = chronic myelogenous leukemia; CP = chronic phase; MDS = myelodysplastic syndrome; RA = refractory anemia; ML = mixed leukemia; AML = acute myelogenous leukemia; BU = busulfan; CY = cyclophosphamide; TBI = total body irradiation; TLI = total lymph node irradiation; CsA = cyclosporin A, MTX = methotrexate; mPSL = methyl prednisolone; R = related; UR = unrelated; TM = thrombotic microangiopathy.
ipheral blood were checked for CMV-DNA on day 35 after BMT by the polymerase chain reaction method and by the direct immunoperoxidase method (CMV antigen screening), using an HRP-C7 peroxidase-labeled monoclonal antibody directed against matrix protein p65 of CMV. 14 Subsequently, only the peripheral blood was rechecked until day 100. If either specimen was positive, ganciclovir was administered by the method of Singhal et al. 15 Granulocyte colony-stimulating factor (G-CSF) (lenograstim (5 g/kg), filgrastim (5 g/kg) or nartrograstim (8 g/kg)) was administered to all patients from day 5 until the WBC exceeded 10 ϫ 10 9 /l. During the post-transplantation period, erythrocyte fragmentation, red blood cell count (RBC), platelet count, and LDH level were assessed three times a week. Various cytokines (TNF-␣, IFN-␥, IL-1-␤, IL-2, IL-6, IL-8, IL-10 and IL-12) and intercellular adhesion molecule-1 (ICAM-1) were determined on five occasions: before conditioning, day 0 (before bone marrow infusion), during the aplastic phase (days 5-10), during recovery of the white blood cell count (WBC) (days 11-20: when the peripheral WBC was around 2 ϫ 10 9 /l and increasing most rapidly), and at the time of WBC stabilization after discontinuation of G-CSF (days [21] [22] [23] [24] [25] [26] [27] [28] .
Blood samples were collected into tubes containing 3.8% citric acid at a ratio of 1:9. After separation by centrifugation at 1500 g for 10 min at 4°C, plasma was stored at Ϫ80°C. All parameters were measured twice at each specified time by ELISA using kits from Endogen (Woburn, MA, USA) and the mean values were determined. Statistical analysis was done using two-way layout analysis of variance as was appropriate, and P Ͻ 0.05 was considered to indicate a significant difference.
Results
TM occurred after BMT in three out of 12 patients and the clinical details of these three patients are summarized in Table 1 . In these three patients (cases 1, 2 and 3), TM occurred on days 30, 23 and 60 after BMT, respectively.
In case 1, it occurred immediately after pulse therapy with methyl prednisolone for grade 3 acute GVHD. In case 2, it occurred immediately after CMV infection, and it occurred immediately after grade 3 acute GVHD in case 3. TM was grade 2 according to Zeigler's classification and manifested with mild edema and hypertension in all three patients. Clinical characteristics were compared between these three patients with TM and the nine patients without TM. There were no significant differences in age, sex, total body irradiation, donor type, number of months from diagnosis until transplantation, number of days until leukocyte recovery (ANC Ͼ0.5 ϫ 10 9 /l) and platelet recovery (platelet Ͼ50 ϫ 10 9 /l), CMV infection, severity of acute GVHD, and febrile period. In addition, the patients with TM became febrile on day 6 on average, while four of the patients without TM became febrile on day 5.4, so the difference in length of the afebrile period after BMT was not significant. Case 1 showed neurological symptoms and renal dysfunction from around day 110, indicating onset of thrombotic thrombocytopenic purpura and hemolyticuremic syndrome (TTP/HUS). The three patients with TM all had grade 3 acute GVHD, but the severity of GVHD did not always correlate with the extent of red cell fragmentation. The blood level of CsA also did not always correlate with the extent of red cell fragmentation. With respect to CMV infection, the three patients were all positive for CMV by either PCR or antigen screening, but it was difficult to conclude that CMV induced TM because viral markers only became positive after the onset of TM in cases 1 and 2. All three patients also underwent either TBI or total lymph node irradiation. Various cytokines and ICAM-1 were studied from before conditioning until stable recovery of the WBC and these parameters were compared between patients with and without TM. The only significant difference in cytokines was a marked increase of interleukin-12 (IL-12) that occurred by the WBC recovery phase in the patients with TM (two-way layout analysis of variance; P Ͻ 0.05) (Figure 1a ). There were no significant differences between the two groups with respect to the other parameters studied, including TNF-␣, IL-6 (Figure 1b and c) , IL-1␤, IL-2, IL-8, IL-10, and ICAM-1 (data not shown).
Discussion
Holler et al 3 reported that there was a significant correlation between GVHD and TM. The mechanism appears to be either that increased production of interferon-␥ (IFN-␥) and TNF-␣ directly causes endothelial damage that leads to GVHD, or else that upregulation of the expression of class II HLA antigens on endothelial cells subsequently leads to endothelial damage and GVHD. 5, 7, [16] [17] [18] Concerning the relationship between CsA and TM, it has been reported that progress of this condition is not influenced when CsA therapy is discontinued and that there is no correlation between CsA concentration during treatment and severity of TM. 3, 4 Various mechanisms for TM have been suggested, including extensive microthrombosis in various organs due to inhibition of prostaglandin I 2 synthesis by CsA, 19 reduction of protein C activity by CsA via the thrombin/ thrombomodulin complex, 20 and increased platelet aggregation as a result of the interaction of CsA with adrenaline, collagen or ADP. 21 CMV infection is closely related to TM, [2] [3] [4] [5] but the mechanism appears to involve promotion of an inherent tendency for GVHD when T cells attack CMVinfected endothelial cells with altered surface antigens. 5 It has been reported that donor T cells increase IL-2 release and cause T cell activation, and that activated T lymphocytes produce IFN-␥ which activates monocytes and promotes the production of both IL-1 and TNF-␣. Subsequently, IFN-␥ and TNF-␣ enhance class II MHC antigen expression on endothelial cells, and this appears to result in endothelial damage in the course of GVHD. 5, 7, [16] [17] [18] Previous studies on cytokines involved in TTP/HUS have suggested a role for TNF-␣ and IL-6. 22 In the present study, however, neither of these cytokines showed any significant differences between patients with and without TM (Figure 1b and c) . Only IL-12 showed a significant increase between the aplastic phase and the recovery phase in the patients with TM when compared to those without TM (Figure 1a) . One of the earliest detectable changes indicating recovery after BMT is the production of macrophage-derived cytokines, suggesting that macrophage activation might increase at the time of engraftment. IL-12 is one of the macrophage-derived cytokines, being produced by monocytes, macrophages, dendritic cells, and B cells after stimulation by bacteria, bacterial products, and intracellular parasites. 23 One of its main functions is as a proinflammatory cytokine that activates natural killer cells and T cells, promotes the release of IFN-␥, and activates phagocytic cells. 23, 24 Another function is as an immunomodulator that regulates the immune response by promoting the differentiation of Th0 cells to Th1 cells and inhibiting differentiation to Th2 cells. 23, [25] [26] [27] [28] Other actions which have been reported include induction of vascular permeability factor, 25 release of other cytokines (such as TNF-␣, IL-8 and IL-2) by induction of natural killer cells and T cells, and aggravation of acute GVHD. 29 In summary, BMT was complicated by TM following exposure to stimuli such as severe GVHD, CMV infection, and high CsA concentrations when patients had become Various cytokines and ICAM-1 were measured five times: before conditioning, day 0 (before bone marrow infusion), during the aplastic phase (days 5-10), during rapid recovery of WBC (days [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , and during the stable phase after WBC recovery and discontinuation of G-CSF (days [21] [22] [23] [24] [25] [26] [27] [28] . The only significant difference in cytokines between the patients with and without TM was a marked increase of interleukin-12 (IL-12) that occurred by the WBC recovery phase in the patients with TM (two-way layout analysis of variance; P Ͻ 0.05) (a). There were no significant differences between the two groups with respect to TNF-␣, IL-6 (b and c), IFN-␥, IL-1␤, IL-2, IL-8, IL-10 and ICAM-1 (data not shown). Black circles show patients with TM and white circles show nine non-TM patients. febrile secondary to infection during the aplastic phase and then suffered a rapid increase of IL-12 in the recovery phase. This increase of IL-12 in the recovery phase continued the priming of vascular endothelial cells, leading to the rapid onset of TM when the primed cells were exposed to appropriate stimuli (eg severe GVHD, CMV infection and high CsA concentration).
In the present study, we investigated changes of various cytokines and an adhesion molecule during the early stage after transplantation in patients with TM. A significant correlation was found between elevation of IL-12 at the time of leukocyte recovery after transplantation and the development of TM. This suggested the possibility that inflammation or an autoimmune mechanism are one of the factors causing TM, but our data are preliminary because of small patient numbers.
